Know Cancer

forgot password

Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib

Phase 2
18 Years
Not Enrolling
Gastrointestinal Stromal Tumors

Thank you

Trial Information

Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib

Nilotinib is an oral drug. The dose is 400 mg twice daily

Patients are evaluated every 8 weeks for disease response. Blood work is assessed for safety
initially weekly, then every 4 weeks. Physical exams are performed initially weekly and
then decreased to every 4 weeks after the first month.

Inclusion Criteria

Inclusion Criteria

- Patients must have histologically or cytologically confirmed GIST

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as >=
20 millimeters (mm) with conventional techniques or as >= 10 mm with spiral CT scan.

- Patients may have received prior chemotherapy or radiation therapy. Patients must
have recovered from any prior therapy and at least 4 weeks (6 weeks for nitrosoureas
or mitomycin C; 2 weeks for limited field palliative radiation) must have elapsed
since prior treatment.

- Patients must have received and progressed on imatinib and sunitinib. Except for
nilotinib, patients may have received additional tyrosine kinase inhibitors or
additional targeted therapies.

- Age >= 18 years.

- Life expectancy of greater than 12 weeks.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Patients must have normal organ and marrow function as defined below:

- absolute neutrophil count >= 1,500/mcL

- platelets >= 100,000/mcL

- total bilirubin <= 1.5 times Upper Limits of Normal (ULN)

- AST(SGOT)/ALT(SGPT) <= 2.5 X ULN OR <= 5.0 X ULN if considered due to tumor

- Potassium, magnesium normal or corrected to normal limits prior to initiating

- Calcium, phosphorus normal or corrected to normal limits prior to initiating

- creatinine within normal institutional limits

- creatinine clearance 24 hour creatinine clearance >= 50 mL/min (calculation by
cockroft formula is acceptable)

- The effects of Nilotinib on the developing human fetus at the recommended therapeutic
dose are unknown. Men or women of childbearing potential (WOCBP), to include female
partners of heterosexual or bisexual patients, must agree to use an effective method
of contraception during the study and for up to three months following termination of
the study. Post menopausal women must be amenorrheic for at least 12 months to be
considered of non-childbearing potential.

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

- Patients may not be receiving any other investigational agents within 4 weeks.

- Prior or concomitant malignancies (with a relapse in the last 5 years or requiring
active treatment) other than GIST and with the exception of previous or concomitant
basal cell skin cancer, previous cervical carcinoma in situ

- Impaired cardiac function at baseline, including any one of the following:

- Left Ventricular Ejection Fraction (LVEF)< 45% or below the institutional Lower
Limits of Normal (LLN) range (whichever is higher)

- Complete left bundle branch block

- Use of a ventricular paced cardiac pacemaker

- Congenital long QT syndrome or family history of long QT syndrome

- History of or presence of significant ventricular or atrial tachyarrhythmias

- Clinically significant resting bradycardia (< 50 beats per minute)

- QTc > 450 msec on screening ECG (using the QTcF formula). If QTc > 450 msec and
electrolytes are not within normal ranges (electrolytes should be corrected and
then the patient rescreened for QTc.

- Right bundle branch block plus left anterior hemiblock, bifascicular block

- Myocardial infarction within 12 months prior to Visit 1

- Other clinically significant heart disease (e.g., unstable angina, congestive
heart failure or uncontrolled hypertension)

- Patients with severe and/or uncontrolled concurrent medical disease that in the
opinion of the investigator could cause unacceptable safety risks or compromise
compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI
disease that may significantly alter the absorption of the study drugs, uncontrolled

- Use of therapeutic coumarin derivatives (i.e. warfarin, acenoucumarol, phenprocoumon)

- Use of any medications that prolong the QT interval and CYP3A4 inhibitors if the
treatment cannot be either safely discontinued or switched to a different medication
prior to starting study drug administration. Please see for a
comprehensive list of agents that prolong the QT interval as well as

- Patients who have undergone major surgery <= 2 weeks prior to Visit 1 or who have not
recovered from side effects of such surgery

- A history of noncompliance to medical regimens or inability or unwillingness to
return for scheduled visits, patients who are pregnant or breast feeding, and
patients unwilling or unable to comply with the requirements for the protocol.

- Patient has known chronic liver disease (i.e., chronic active hepatitis, and

- Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival Rate at 6 Months

Outcome Description:

Number of participants that demonstrate progression free survival at 6 months

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Margaret von Mehren, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fox Chase Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

July 2008

Completion Date:

October 2009

Related Keywords:

  • Gastrointestinal Stromal Tumors
  • GIST
  • Nilotinib
  • Gastrointestinal Stromal Tumors



Fox Chase Cancer Center Philadelphia, Pennsylvania  19111